SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Avadel Pharmaceuticals plc AVDL NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • IE • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Avadel Pharmaceuticals plc (AVDL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $21.64. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is AVDL = $20 (-7.6% upside).

Financials: revenue is $169M, +504.8%/yr average growth. Net income is $49M (loss), growing at -8.3%/yr. Net profit margin is -28.9% (negative). Gross margin is 91% (-6 pp trend).

Balance sheet: total debt is $2M against $74M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 2.75 (strong liquidity). Debt-to-assets is 1%. Total assets: $164M.

Analyst outlook: 8 / 14 analysts rate AVDL as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 55/100 (Partial), Future 38/100 (Fail), Income 10/100 (Fail).

$20.00

▼ 7.58% Downside

Average Price Target

Based on 14 Wall Street analysts offering 12-month price targets for Avadel Pharmaceuticals plc, the average price target is $20.00, with a high forecast of $21.00, and a low forecast of $19.00.

Highest Price Target

$21.00

Average Price Target

$20.00

Lowest Price Target

$19.00

AVDL SharesGrow Score Overview

44/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 35/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 55/100

Gross margin is + market cap

FUTURE 38/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AVDL

AVDL trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $20, implying -7.6% from the current price $22. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

AVDL: +504.8%/yr revenue is, -8.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet AVDL: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 2.75 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

AVDL: Gross margin is 91% (-6 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 55/100. ≥ 70 = Pass.

View details →

Analyst outlook: 8 / 14 analysts rate AVDL as buy (57%). Analyst consensus target is $20 (-7.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

AVDL: Net profit margin is -28.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range6.38-23.57

Volume35.02M

Avg Volume (30D)2.42M

Market Cap$2.12B

Beta (1Y)1.31

Share Statistics

EPS (TTM)-0.51

Shares Outstanding$95.14M

IPO Date1996-06-07

Employees188

CEOGregory J. Divis Jr.

Financial Highlights & Ratios

Revenue (TTM)$169.12M

Gross Profit$153.84M

EBITDA$-35.57M

Net Income$-48.83M

Operating Income$-42.4M

Total Cash$73.78M

Total Debt$1.7M

Net Debt$-49.67M

Total Assets$164.24M

Price / Earnings (P/E)-42.4

Price / Sales (P/S)12.56

Analyst Forecast

1Y Price Target$20.00

Target High$21.00

Target Low$19.00

Upside-7.6%

Rating ConsensusBuy

Analysts Covering14

Buy 57% Hold 43% Sell 0%

Price Target Summary

Company Info

CountryIE

ExchangeNASDAQ Global Market

CurrencyUSD

ISINIE00BDGMC594

Price Chart

AVDL

Avadel Pharmaceuticals plc ↗ · NASDAQ Global Market

Healthcare • Drug Manufacturers - Specialty & Generic

6.38 52WK RANGE 23.57

People Also View

Intra-Cellular Therapies, Inc.

Neurocrine Biosciences, Inc.

Amneal Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc.

Dynavax Technologies Corporation

ANI Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message